MRI-Guided Radiotherapy for Prostate Cancer: Seeing is Believing

Rosalyne L Westley; Luca F Valle; Alison C Tree; Amar U Kishan

doi:10.1016/j.semradonc.2023.10.001

MRI-Guided Radiotherapy for Prostate Cancer: Seeing is Believing

Semin Radiat Oncol. 2024 Jan;34(1):45-55. doi: 10.1016/j.semradonc.2023.10.001.

Authors

Rosalyne L Westley¹, Luca F Valle², Alison C Tree³, Amar U Kishan⁴

Affiliations

¹ The Royal Marsden Hospital, Sutton, England, UK; The Institute of Cancer Research, Sutton, England, UK. Electronic address: Rosalyne.westley@rmh.nhs.uk.
² Department of Radiation Oncology, University of California, Los Angeles, CA, USA. Electronic address: lfvalle@mednet.ucla.edu.
³ The Royal Marsden Hospital, Sutton, England, UK; The Institute of Cancer Research, Sutton, England, UK.
⁴ Department of Radiation Oncology, University of California, Los Angeles, CA, USA.

PMID: 38105093
DOI: 10.1016/j.semradonc.2023.10.001

Abstract

The advent of MRI guided radiotherapy (MRIgRT) offers enormous promise in the treatment of prostate cancer. The MR-linac offers men the opportunity to receive daily MR imaging to guide and influence their radiotherapy treatment. This review focuses on the advantages that MRIgRT potentially offers as well as any potential disadvantages to MRIgRT that may have been recognized thus far. Ongoing clinical trials evaluating this novel treatment platform for the treatment of prostate cancer are also discussed.

Published by Elsevier Inc.

Publication types

Review

MeSH terms

Humans
Magnetic Resonance Imaging / methods
Male
Particle Accelerators
Prostatic Neoplasms* / diagnostic imaging
Prostatic Neoplasms* / radiotherapy
Radiotherapy, Image-Guided* / methods